# Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

> **NCT01765790** · PHASE1 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Adenocarcinoma of the Colon or Rectum
- Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- **BIOLOGICAL:** Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

## Key facts

- **NCT ID:** NCT01765790
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-14
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-07-28
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01765790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01765790, "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01765790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*